undamentalytics Newsletter

Dare Bioscience vs Medicinova

Dare Bioscience is the larger business, with $1.0m of revenue in fiscal 2025 against $409,657 for Medicinova (2.5 times as much). Dare Bioscience grew faster (10429.4% against -59.0%). Dare Bioscience kept more of each dollar of sales as profit: a net margin of -1300.7% against -2928.8%. Dare Bioscience carries less debt relative to equity (0.0% against 0.0%).

Latest fiscal yearDare BioscienceDARE, 2025MedicinovaMNOV, 2025
Revenue $1.0m $409,657
Revenue growth 10429.4% -59.0%
Net income −$13.4m −$12.0m
Operating margin -1315.5% -3242.5%
Net margin -1300.7% -2928.8%
Return on equity — -23.1%
Free cash flow −$10.3m −$9.8m
Cash $24.7m $30.8m
Total debt $0 $0
Debt to equity 0.0% 0.0%
Dividend per share — —
Dividend yield — —
Share buybacks — —
Employees 24 —
Market value $9.7m $70.9m
Price vs our value range — —
Moat score — —
Insider trades, 12 months 0 buys, 0 sales 0 buys, 1 sales

Each figure is from the company's latest annual report and links to the page it comes from. Fiscal years can end on different dates. Market value and the value verdict use the delayed price shown on the stock pages. Not a recommendation.

Go deeper

Figures from each company's latest annual report filed with the SEC (10-K or 20-F), as reported, with the fiscal year shown. Not investment advice. How we read filings: methodology.